Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

HCAT


Top 10 Correlated Stocks

HCAT


In the News

08:05 13 Aug 2022 HCAT

Health Catalyst to Participate in Upcoming Investor Conference

SALT LAKE CITY, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Bryan Hunt, Chief Financial Officer, and Adam Brown, Senior Vice President of Investor Relations and FP&A, will participate in the Canaccord Genuity 42nd Annual Growth Conference, being held in Boston on Thursday, August 11, 2022, including a fireside chat presentation at 12:00pm ET. The replay of the presentation will be available online at https://ir.healthcatalyst.com.

12:41 13 Aug 2022 HCAT

Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q2 2022 Results - Earnings Call Transcript

Health Catalyst, Inc. (NASDAQ:HCAT ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Adam Brown – Senior Vice President-Finance and Investor Relations Dan Burton – Chief Executive Officer Bryan Hunt – Chief Financial Officer Conference Call Participants Anne Samuel – J.P. Morgan Jared Haase – William Blair Elizabeth Anderson – Evercore Stephanie Davis – SVB Securities John Ransom – Raymond James Jessica Tassan – Piper Sandler Richard Close – Canaccord Genuity Daniel Grosslight – Citi Rohan Chandrasekhar – Guggenheim Partners Operator Good day, ladies and gentlemen, and thank you for standing by.

07:33 13 Aug 2022 HCAT

Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

07:00 13 Aug 2022 HCAT

7 Small-Cap Growth Stocks Trading at a Huge Discount Right Now

When equities are under pressure, it is particularly important for investors to find stocks that are trading at a discount to their intrinsic value. This can be particularly difficult if you're interested in finding small-cap growth stocks trading at a discount.

04:05 13 Aug 2022 HCAT

Health Catalyst to Announce Second Quarter 2022 Operating Results and Host Conference Call on Thursday, August 4, 2022

SALT LAKE CITY, July 21, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its second quarter 2022 operating results on Thursday, August 4, 2022, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.

04:05 13 Aug 2022 HCAT

Health Catalyst to Participate in Upcoming Investor Conferences

SALT LAKE CITY, June 01, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Bryan Hunt, Chief Financial Officer, and Adam Brown, Senior Vice President of Investor Relations and FP&A, will participate in the following upcoming investor conferences:

03:51 13 Aug 2022 HCAT

Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q1 2022 Results - Earnings Call Transcript

Health Catalyst, Inc. (NASDAQ:HCAT ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Adam Brown - IR Dan Burton - CEO Bryan Hunt - CFO Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Cindy Motz - Goldman Sachs Elizabeth Anderson - Evercore Stephanie Davis - SVB Securities Richard Close - Canaccord Genuity John Ransom - Raymond James Daniel Grosslight - Citi David Larsen - BTIG Dev Weerasuriya - Berenberg Operator Good day, and thank you for standing by. Welcome to the Health Catalyst First Quarter 2022 Earnings Conference Call.

07:34 13 Aug 2022 HCAT

Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 25% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

04:05 13 Aug 2022 HCAT

Health Catalyst to Announce First Quarter 2022 Operating Results and Host Conference Call on Tuesday, May 10, 2022

SALT LAKE CITY, April 26, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2022 operating results on Tuesday, May 10, 2022, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.

02:30 13 Aug 2022 HCAT

Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q4 2021 Results - Earnings Call Transcript

Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q4 2021 Results - Earnings Call Transcript

Financial details

Company Rating
Buy
Market Cap
621.11M
Income
-144.89M
Revenue
265.17M
Book val./share
8.74
Cash/share
7.51
Dividend
-
Dividend %
-
Employees
1.2K
Optionable
No
Shortable
Yes
Earnings
07 Nov 2022
P/E
-4.92
Forward P/E
-9.35
PEG
13.02
P/S
2.69
P/B
1.52
P/C
1.77
P/FCF
-19.05
Quick Ratio
5
Current Ratio
5.15
Debt / Equity
0.52
LT Debt / Equity
0.52
-
-
EPS (TTM)
-2.8
EPS next Y
-1.42
EPS next Q
-0.63
EPS this Y
11%
EPS next Y
-49.29%
EPS next 5Y
-49.29%
EPS last 5Y
8.82%
Revenue last 5Y
27.05%
Revenue Q/Q
3.74%
EPS Q/Q
47.62%
-
-
-
-
SMA20
-12.43%
SMA50
-0.98%
SMA100
-39.87%
Inst Own
100%
Inst Trans
0%
ROA
-18%
ROE
-29%
ROC
-0.2%
Gross Margin
41%
Oper. Margin
-55%
Profit Margin
-55%
Payout
-
Shs Outstand
54.72M
Shs Float
54.03M
-
-
-
-
Target Price
45.33
52W Range
10.95-58.03
52W High
-77.1%
52W Low
+32.8%
RSI
41.93
Rel Volume
1.43
Avg Volume
1.08M
Volume
1.54M
Perf Week
-25.81%
Perf Month
-8.35%
Perf Quarter
-51.1%
Perf Half Y
-56.03%
-
-
-
-
Beta
1.07447
-
-
Volatility
2.19%, 1.8%
Prev Close
3.51%
Price
13.28
Change
4.57%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2019-12-312020-12-31 2021-12-31
Revenue per share
8.274.785.09
Net income per share
-3.21-2.91-3.23
Operating cash flow per share
-1.72-0.66-0.49
Free cash flow per share
-1.95-0.86-0.85
Cash per share
12.186.859.37
Book value per share
10.716.9810.99
Tangible book value per share
9.151.045.21
Share holders equity per share
10.716.9810.99
Interest debt per share
2.915.173.61
Market cap
624.26M1.96B1.35B
Enterprise value
654.43M2.07B1.34B
P/E ratio
-10.39-17.08-8.79
Price to sales ratio
4.0310.45.57
POCF ratio
-19.4-75.13-58.23
PFCF ratio
-17.09-57.91-33.48
P/B Ratio
3.117.112.58
PTB ratio
3.117.112.58
EV to sales
4.2210.945.54
Enterprise value over EBITDA
-14.71-24.04-9.65
EV to operating cash flow
-20.33-78.98-58
EV to free cash flow
-17.92-60.88-33.35
Earnings yield
-0.1-0.06-0.11
Free cash flow yield
-0.06-0.02-0.03
Debt to equity
0.240.610.35
Debt to assets
0.340.550.37
Net debt to EBITDA
-0.68-1.170.04
Current ratio
5.483.755.46
Interest coverage
-8.76-8.318.73
Income quality
0.540.230.15
Dividend Yield
000
Payout ratio
000
Sales general and administrative to revenue
0.20.310.36
Research and developement to revenue
0.30.280.26
Intangibles to total assets
0.10.380.33
Capex to operating cash flow
0.130.30.74
Capex to revenue
-0.03-0.04-0.07
Capex to depreciation
-0.47-0.42-0.46
Stock based compensation to revenue
0.120.20.27
Graham number
27.7921.3828.25
ROIC
-0.22-0.21-0.19
Return on tangible assets
-0.22-0.34-0.27
Graham Net
7.860.143.61
Working capital
216.02M241.76M415.34M
Tangible asset value
171.42M41.02M247.34M
Net current asset value
162.52M28.16M198.39M
Invested capital
0.240.70.36
Average receivables
37.93M48.3M48.55M
Average payables
4.48M5.33M5.01M
Average inventory
000
Days sales outstanding
64.9593.3573.63
Days payables outstanding
17.5519.8413.77
Days of inventory on hand
000
Receivables turnover
5.623.914.96
Payables turnover
20.818.3926.5
Inventory turnover
000
ROE
-0.3-0.42-0.29
Capex per share
-0.23-0.2-0.36

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
1.331.261.241.281.32
Net income per share
-0.8-0.82-0.94-0.42-0.62
Operating cash flow per share
-0.11-0.11-0.190.02-0.18
Free cash flow per share
-0.19-0.19-0.23-0.06-0.24
Cash per share
5.859.298.548.037.51
Book value per share
6.1511.2110.029.078.74
Tangible book value per share
1.835.434.753.553.23
Share holders equity per share
6.1511.2110.029.078.74
Interest debt per share
4.544.223.524.724.65
Market cap
2.49B2.45B2.06B1.39B777.75M
Enterprise value
2.49B2.38B2.06B1.44B849.18M
P/E ratio
-17.38-15.31-10.54-15.42-5.82
Price to sales ratio
41.7939.6931.9120.3411.01
POCF ratio
-514.27-457.17-211.241.2K-81.22
PFCF ratio
-296.06-264.14-170.2-474.01-59.46
P/B Ratio
9.034.463.952.881.66
PTB ratio
9.034.463.952.881.66
EV to sales
41.738.531.8221.0812.02
Enterprise value over EBITDA
-104.82-75.31-48.35-114.31257.09
EV to operating cash flow
-513.15-443.42-210.681.24K-88.68
EV to free cash flow
-295.41-256.2-169.75-491.14-64.92
Earnings yield
-0.01-0.02-0.02-0.02-0.04
Free cash flow yield
00-0.010-0.02
Debt to equity
0.080.040.350.510.52
Debt to assets
0.510.350.370.420.42
Net debt to EBITDA
0.232.330.13-3.9921.63
Current ratio
1.261.965.465.215.15
Interest coverage
-7.75-9.4710.23-13.49-28.13
Income quality
0.140.130.2-0.050.29
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.380.370.390.130.25
Research and developement to revenue
0.240.270.270.250.26
Intangibles to total assets
0.340.340.330.350.36
Capex to operating cash flow
0.740.730.24-3.520.37
Capex to revenue
-0.06-0.06-0.04-0.06-0.05
Capex to depreciation
-0.44-0.37-0.22-0.35-0.27
Stock based compensation to revenue
0.30.280.250.270.25
Graham number
10.5114.3514.569.311.07
ROIC
-0.1-0.07-0.06-0.03-0.05
Return on tangible assets
-0.1-0.07-0.09-0.04-0.06
Graham Net
0.243.973.292.141.8
Working capital
66.46M251.97M415.34M389.84M375.06M
Tangible asset value
82.17M265.96M247.34M188.4M173.57M
Net current asset value
34M219.03M198.39M138.48M123.09M
Invested capital
0.720.370.360.520.53
Average receivables
44.8M45.15M45.71M42.63M45.19M
Average payables
5.56M5.32M5.28M5.87M5.78M
Average inventory
00000
Days sales outstanding
70.969.5167.8756.3560.85
Days payables outstanding
15.7512.9812.4715.539.28
Days of inventory on hand
00000
Receivables turnover
1.271.291.331.61.48
Payables turnover
5.716.937.225.89.7
Inventory turnover
00000
ROE
-0.13-0.07-0.09-0.05-0.07
Capex per share
-0.08-0.08-0.05-0.08-0.07

Something similar

Same Sector
Top Correlated Stocks